A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Active:	Yes
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT06841354
Trial Phases:	Phase III	Protocol IDs:	2870-011 (primary) NCI-2025-02693 2024-516834-36 2024-516834-36-00 MK-2870-011 TroFuse-011 U1111-1311-2310
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06841354

Summary

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can
treat triple negative breast cancer (TNBC). The main goal of this study is to learn if
people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer
overall or without the cancer growing or spreading compared to people treated with
chemotherapy.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.